Regulations Governing Medicines for Maternal and Neonatal Health: A Landscape Assessment

• Published in: Therapeutic innovation & regulatory science Vol. 58; no. 2; pp. 242 - 257
• Main Authors: Alexe, Amalia, Garg, Anju, Kovacs, Birgit, Abramova, Nadezda, Apara, Olatayo, Eisele, Osa, Fernandes, Maria Fernanda Scantamburlo, Balramsingh-Harry, Leesha, Wurst, Keele, Lewis, David
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.03.2024; Springer Nature B.V
• Subjects: Asia; Breast feeding; Breastfeeding & lactation; Clinical trials; Drug Safety and Pharmacovigilance; Europe; Female; Humans; Infant Health; Infant, Newborn; Legislation; Medicine; Neonates; Organizations; Pharmacotherapy; Pharmacovigilance; Pharmacy; Pregnancy; Regulations; Review; Safety; Asia; Europe; Pregnancy; Patient safety; Breastfeeding; Pharmacovigilance regulations
• ISSN: 2168-4790; 2168-4804
• DOI: 10.1007/s43441-023-00593-3

Limited evidence related to the safety or efficacy of medicines in pregnancy and during breastfeeding is available to inform patients and healthcare professionals. Understanding the current regulatory landscape in the clinical trial and postmarketing settings is critical to facilitate the development of applicable processes and tools for studying medicine use during pregnancy and breastfeeding and comply with health authority expectations. This review summarizes key findings from a landscape assessment of regulations, guidelines, and guidance on the use of medicines in pregnancy and breastfeeding issued by health authorities in various territories (including the Americas, Europe, Africa, and Asia Pacific) and outlines relevant initiatives undertaken by health authorities, academic institutions, industry consortia, and public–private organizations. While global pharmacovigilance legislation regarding medication use during pregnancy and breastfeeding exists and continues to evolve, the landscape assessment revealed that there is a lack of global legislative harmonization in both the clinical trial and postmarketing surveillance settings and regulatory gaps still exist in many countries/regions. Despite ongoing efforts from health authorities and public and private organizations, intensive efforts for legislation harmonization and stakeholder collaboration are required to improve the current environment of medication safety in pregnancy and breastfeeding.